Core Viewpoint - The oral COVID-19 drug VV116 shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready-made treatment option amid the absence of approved vaccines or specific therapies for Nipah virus infections [2][4][7]. Group 1: Research Findings - Recent studies published in the journal "Emerging Microbes & Infections" confirm that VV116 can increase the survival rate of infected golden hamsters to 66.7% and significantly reduce viral loads in key organs [4][6]. - The research indicates that VV116 exhibits notable inhibitory effects against two main strains of the Nipah virus, NiV-M and NiV-B, in vitro and in animal models [6][8]. - The Nipah virus has a mortality rate ranging from 32% to 70%, with recent outbreaks reported in India, raising public health concerns [6][7]. Group 2: Company Responses - Junshi Bioscience stated that they have not conducted similar research and that expanding indications would require clinical data support [2][12]. - In contrast, Wangshan Wangshui expressed their intent to closely monitor the epidemic's developments and initiate clinical trials for treatment or post-exposure prevention as needed [2][12]. Group 3: Market Impact - Following the announcement, Wangshan Wangshui's stock price surged nearly 15% during trading on January 27, closing at 108.9 HKD per share, marking a 10.90% increase and a historical high [3]. - Junshi Bioscience's stock also rose by 7.96% on the same day [3]. Group 4: Broader Implications - VV116, developed through collaboration among several Chinese research institutions, is positioned as a broad-spectrum antiviral drug with potential applications beyond COVID-19, including against other RNA viruses [8][10]. - The drug's mechanism targets the highly conserved RNA-dependent RNA polymerase (RdRp) of RNA viruses, suggesting its effectiveness against future viral variants [8][10]. Group 5: Financial Context - Wangshan Wangshui reported that VV116 generated significant revenue, accounting for 98% of the company's total revenue in 2023, but faces challenges as demand for COVID-19 treatments declines [13]. - The company has experienced financial losses in the post-pandemic era, with net losses of approximately 218 million CNY in 2024 and 112 million CNY in the first four months of 2025 [13].